Influvac Sub-Unit (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains purified hemagglutinin subunits from selected influenza strains. After injection, these antigens are processed by antigen‑presenting cells, activating T‑cells and prompting B‑cells to produce strain‑specific neutralizing antibodies. The resulting adaptive immune response provides protection against future exposure to the matched influenza viruses.

The dosage and schedule of Influvac Sub-Unit are determined by the prescribing healthcare professional based on age, health status, and local immunization guidelines. The prescriber will select the appropriate volume and route (intramuscular or subcutaneous) for each individual patient.

Safety data for Influvac Sub-Unit in pregnancy are limited, and the product is classified as pregnancy category unknown. Healthcare providers should assess the potential benefits and risks before vaccinating pregnant or breastfeeding individuals. When benefits outweigh potential risks, vaccination may be considered.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain handling), and any required import documentation.

Influvac Sub-Unit is a subunit vaccine that uses purified hemagglutinin proteins, offering a well‑tolerated safety profile compared with whole‑virus or live‑attenuated vaccines. It does not contain live virus, reducing the risk of replication‑related adverse events, and is suitable for individuals with certain contraindications to live vaccines.

The vaccine must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Influvac Sub-Unit is administered by a trained healthcare professional via intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm. The injection site should be cleaned with an appropriate antiseptic, and the dose is given as a single vial per vaccination episode.

Serious but rare risks include anaphylaxis, Guillain‑Barré syndrome, severe allergic reactions, seizures, high‑grade fever, and extensive skin rash. Patients should be observed for a short period after vaccination, and any signs of severe reaction should be treated promptly and reported to medical authorities.

Individuals with a known severe allergy to any component of the vaccine, including egg protein if present, should not receive Influvac Sub-Unit. Those who have experienced a previous severe reaction to a similar influenza subunit vaccine should also avoid it. Consultation with a healthcare provider is essential for anyone with contraindications.